2023 Viruses and Cells Gordon Research Conference and Gordon Research Seminar
2023病毒与细胞戈登研究大会暨戈登研究研讨会
基本信息
- 批准号:10609208
- 负责人:
- 金额:$ 0.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-02-10 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:AnimalsAntiviral TherapyApplications GrantsArbovirusesAreaAttentionBiologyCOVID-19 pandemicCellsChildhoodCollaborationsCulicidaeDisease OutbreaksEbola virusEnsureEnvironmentEvolutionExplosionExposure toFacultyFosteringFundingFutureGenderGeographic LocationsGoalsHIVHealth systemHepatitis B VirusHerpesviridaeHumanImmune responseIndividualIndustryInfantInfluenzaInternationalMalignant NeoplasmsMentorshipMorbidity - disease ratePathogenesisPersonsPopulationPostdoctoral FellowPublic HealthResearchResearch PersonnelScientistSecureSeminalSystemTherapeuticViralViral CancerViral PathogenesisVirusVirus ReplicationWomanWorkZIKAcareercareer developmentcombatdoctoral studentfood insecurityforgingfuture outbreakgraduate studentinnovationmeetingsmortalitynovelnovel therapeutic interventionpandemic diseasepathogenpeerpostersprogramsrecruitrespiratoryresponsestudent conferencesymposiumtransmission processvirologyvirus host interaction
项目摘要
PROJECT SUMMARY
The objective of the 2023 Viruses and Cells Gordon Research Conference (GRC) is to highlight the most
significant and impactful virology research and stimulate new collaborations by recruiting a diverse spectrum of
leading-edge virologists from around the globe. We also aim to foster career development opportunities for
graduate students and postdoctoral fellows before the start of the Viruses & Cells GRC for students and
postdoctoral fellows by hosting an associated 2-day Gordon Research Seminar (GRS). The GRS will provide a
unique platform for PhD students, postdoctoral fellows and young researchers to present their cutting-edge
work to an international audience of their peers through both talks selected from abstracts and an evening
poster session. Held every other year since 1995 (with the exception of 2021 due to the pandemic), the
Viruses and Cells GRC is one of the most successful of the prestigious international scientific conferences
organized by the GRC and encompasses a remarkable breadth of seminal virology in an exceptionally
interactive, 200 person setting. These include the most novel aspects of viral replication, viral pathogenesis,
virus-host interactions, and antiviral therapies. Significant attention is being given to the assembly of a program
that is scientifically outstanding and represents a diverse spectrum of virologists. This includes geographic
location, career stage, gender balanced, and inclusive of individuals from underrepresented backgrounds. The
conference will bring together established investigators at the forefront of the field, junior investigators
launching independent research careers, scientists from industry, postdoctoral fellows, and graduate students,
to discuss new ideas and foster collaborations to advance the most innovative and broadly impactful areas of
viral research.
项目摘要
2023年病毒和细胞戈登研究会议(GRC)的目标是突出最
重要和有影响力的病毒学研究,并通过招募各种各样的
来自地球仪的顶尖病毒学家我们还致力于为以下人员提供职业发展机会:
研究生和博士后研究员开始前的病毒和细胞GRC的学生和
通过主办相关的为期2天的戈登研究研讨会(GRS)博士后研究员。GRS将提供一个
为博士生,博士后研究员和年轻的研究人员提供独特的平台,以展示他们的前沿
通过从摘要中选出的演讲和一个晚上,
海报会议。自1995年起每两年举行一次(2021年因疫情原因除外),
病毒与细胞研讨会是最成功的国际科学会议之一
由GRC组织,包括一个非凡的种子病毒学的广度,
互动,200人的设置。这些包括病毒复制,病毒发病机制,
病毒-宿主相互作用和抗病毒疗法。目前正在大力关注一个程序的汇编,
在科学上是杰出的,代表了不同的病毒学家。其中包括地理
地点、职业阶段、性别平衡,并包括来自代表性不足背景的个人。的
会议将汇集在该领域的前沿,初级调查员,
启动独立的研究生涯,来自工业界的科学家,博士后研究员和研究生,
讨论新的想法,促进合作,以推进最具创新性和广泛影响力的领域,
病毒研究
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Britt A Glaunsinger其他文献
Britt A Glaunsinger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Britt A Glaunsinger', 18)}}的其他基金
Functional Characterization of Herpesvirus-Activated Noncoding Retrotransposon RNAs
疱疹病毒激活的非编码反转录转座子 RNA 的功能表征
- 批准号:
9975697 - 财政年份:2019
- 资助金额:
$ 0.7万 - 项目类别:
Regulation of Gammaherpesviral Late Gene Expression
γ疱疹病毒晚期基因表达的调控
- 批准号:
9178643 - 财政年份:2015
- 资助金额:
$ 0.7万 - 项目类别:
Regulation of Gammaherpesviral Late Gene Expression
γ疱疹病毒晚期基因表达的调控
- 批准号:
10368981 - 财政年份:2015
- 资助金额:
$ 0.7万 - 项目类别:
Regulation of Gammaherpesviral Late Gene Expression
γ疱疹病毒晚期基因表达的调控
- 批准号:
10223851 - 财政年份:2015
- 资助金额:
$ 0.7万 - 项目类别:
Regulation of Gammaherpesviral Late Gene Expression
γ疱疹病毒晚期基因表达的调控
- 批准号:
9049040 - 财政年份:2015
- 资助金额:
$ 0.7万 - 项目类别:
Disruption of Cellular RNA Processing by Kaposi's Sarcoma-Associated Herpesvirus
卡波西肉瘤相关疱疹病毒对细胞 RNA 加工的破坏
- 批准号:
9317435 - 财政年份:2015
- 资助金额:
$ 0.7万 - 项目类别:
Regulation of Gammaherpesviral Late Gene Expression
γ疱疹病毒晚期基因表达的调控
- 批准号:
10576837 - 财政年份:2015
- 资助金额:
$ 0.7万 - 项目类别:
Escape from gammaherpesvirus-induced mRNA destruction
逃避伽马疱疹病毒诱导的 mRNA 破坏
- 批准号:
8148069 - 财政年份:2011
- 资助金额:
$ 0.7万 - 项目类别:
Escape from gammaherpesvirus-induced mRNA destruction
逃避伽马疱疹病毒诱导的 mRNA 破坏
- 批准号:
8309954 - 财政年份:2011
- 资助金额:
$ 0.7万 - 项目类别:
Escape from gammaherpesvirus-induced mRNA destruction
逃避伽马疱疹病毒诱导的 mRNA 破坏
- 批准号:
8459030 - 财政年份:2011
- 资助金额:
$ 0.7万 - 项目类别:
相似海外基金
Dose Flexible Combination 3D-Printed Delivery Systems for Antiviral Therapy in Children
用于儿童抗病毒治疗的剂量灵活组合 3D 打印输送系统
- 批准号:
10682185 - 财政年份:2023
- 资助金额:
$ 0.7万 - 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
475843 - 财政年份:2022
- 资助金额:
$ 0.7万 - 项目类别:
Studentship Programs
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
474485 - 财政年份:2022
- 资助金额:
$ 0.7万 - 项目类别:
Studentship Programs
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
- 批准号:
10481430 - 财政年份:2022
- 资助金额:
$ 0.7万 - 项目类别:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
- 批准号:
10683329 - 财政年份:2022
- 资助金额:
$ 0.7万 - 项目类别:
An interdisciplinary approach towards antiviral therapy discovery
抗病毒疗法发现的跨学科方法
- 批准号:
nhmrc : 1196520 - 财政年份:2021
- 资助金额:
$ 0.7万 - 项目类别:
Investigator Grants
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
- 批准号:
10260234 - 财政年份:2021
- 资助金额:
$ 0.7万 - 项目类别:
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
- 批准号:
10548114 - 财政年份:2021
- 资助金额:
$ 0.7万 - 项目类别:
Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study
婴儿潮一代丙型肝炎直接作用抗病毒疗法传播的差异:一项混合方法研究
- 批准号:
10400318 - 财政年份:2020
- 资助金额:
$ 0.7万 - 项目类别:
Development of novel antiviral therapy targeting hepatitis B virus host restriction factor
针对乙型肝炎病毒宿主限制因子的新型抗病毒疗法的开发
- 批准号:
20K08371 - 财政年份:2020
- 资助金额:
$ 0.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




